Abstract:Flow chart of patient enrollment and table of EGFR exon 19 deletion (ex19del) variants, with Kaplan–Meier curve for progression free survival (PFS) and overall survival (OS) of first‐line tyrosine kinase inhibitor (TKI) treatment and incidence of secondary T790M mutation, in EGFR ex19del mutations subgroups. (A, B) Comparison of PFS and OS between the classic and nonclassic EGFR ex19del group; (C) PFS in the EGFR ex19del subgroup with deletion starting at E746 accompanying insertion mutation (E746/ins+), comparing with the patients with other ex19del variants; (D, E), comparison of PFS and OS of first‐line therapy with first‐, second‐, and third‐generation (gen.) tyrosine kinase inhibitor (TKI) in patients with classic EGFR ex19del group; (F, G) comparison of PFS and OS of first‐line therapy with first‐, second‐, and third‐generation (gen.) TKI in patients with nonclassic EGFR ex19del group; (H) incidence of secondary T790M after resistant to first or second generation TKIs, in each subgroup of EGFR ex19del, and comparison between the classic and nonclassic EGFR ex19del groups, between EGFR ex19del subgroups starting at E746 and at other site (ex19del/E746+ vs. ex19del/other site), between EGFR ex19del subgroups with and without insertion mutations (EGFR ex19del/ins+ vs. EGFR ex19del/ins−), and between EGFR ex19del subgroups with deletion length of 15 nucleotides or of other deletion length (ex19del/15+ vs. ex19del/other length). Background Clinical significance of various subtypes of epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) remains unclear. Methods We analyzed EGFR ex19del subtypes in NSCLC patients receiving first‐line tyrosine kinase inhibitor (TKI) therapy at our center (January 2018–June 2022) and correlated them with median progression‐free survival (mPFS) and median overall survival (mOS). Results We identified 17 different EGFR ex19del variants in 101 patients. Between the classic (E746_A750del, 64.4%) and nonclassic groups (the rest variants), no significant difference was observed in mPFS (13.5 vs. 19.3 months, p = 0.18) or mOS (44.1 vs. 77.0 months, p = 0.06). mPFS showed no significant difference between ex19del subgroups classified based on the presence of insertion (ex19delins), starting position or length of deletion. However, patients with ex19delins starting at E746 showed longer mPFS than the others (29.7 vs. 12.5 months, p = 0.04), and patients with ex19del of 15 nucleotides had shorter mOS than the others (44.1 vs. 77.0 months, p = 0.03). In multivariate analysis, ex19delins independently predicted a better PFS (HR = 0.311, p = 0.03); however, 15 nucleotide deletion was no longer associated with OS (HR = 0.181, p = 0.11). Secondary T790M mutation incidence was significantly higher in the ex19del subgroup starting at E746 than the others (64.7% vs. 30.8%, p = 0.04). Conclusions Our study revealed potential differences in TKI efficacy, resistance mechanism, and prognosis of various EGFR ex19del subtypes in NSCLC, underscoring the need for precise selection of first‐line therapy.

Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors.

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study

Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

The Comparison of Egfr-Tki Failure Modes and Subsequent Management Between Exon 19 Deletion and Exon 21 L858r Mutation in Advanced Non-Small-Cell Lung Cancer

Structure-based classification and nomogram prediction for differential inhibitor sensitivity of EGFR exon 19 deletions.

A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and Its Response to EGFR-TKIs

Molecular characteristics of EGFR exon 19 deletion subtypes in NSCLC patients.

Better Survival with Epidermal Growth Factor Receptor Exon 19 Deletion Than with Exon 21 Mutation in Gefitinib-Treated Non-Small Cell Lung Cancer Patients is Due to Differential Inhibition of Downstream Signals

Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis.

Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions

Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis

Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

Real-world Response and Outcomes in Patients with NSCLC with EGFR Exon 20 Insertion Mutations

Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer

Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study